US action date for Acorda's fampridine pushed back to January
This article was originally published in Scrip
Executive Summary
The US FDA has extended by three months the user fee date for Acorda Therapeutics' multiple sclerosis agent fampridine sustained-release (proposed trade name Apriva) following the company's recent submission related to a risk evaluation and mitigation strategy (REMS). The new user fee date is January 22nd.
You may also be interested in...
Puberty Blockers: FDA's Califf Asked If REMS, Boxed Warning Against Off-Label Use In The Works
FDA Commissioner Robert Califf tells House appropriations subcommittee chair the agency will 'consider any information that may be available' on off-label use of puberty blockers for gender dysphoria before making a regulatory decision.
ADHD Drugs: FDA Commissioner Blames Inappropriate Prescribing For Shortages
ADHD drug shortages may have resulted from industry reticence to fill DEA quotas, as well as a 'heavy element of professional responsibility' with off-label prescribing, Robert Califf told a House appropriations subcommittee.
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.